AD/PD™ Neuro Talks Webcast Series
In collaboration with Eisai and Biogen, AD/PD™ presents a new expert interview series exploring the clinical and scientific developments transforming the future of Early Alzheimer’s Disease (AD) diagnosis and care.
Recorded at AD/PD™ 2026, these relaxed and insightful conversations bring together leading international experts and host Dr. Samuel Lockhart to discuss the evolving role of blood-based biomarkers (BBMs) across clinical practice and research.
About the Series
This four-episode series examines key topics surrounding early AD and BBM implementation through expert-led conversations designed for healthcare professionals involved in neurology, dementia care, and cognitive disorders.
Each episode offers practical insights, current evidence, and discussion around the opportunities and challenges facing clinicians today.
Meet Your Host
Dr. Samuel Lockhart is Senior Scientific Director at Perceptive and Adjunct Associate Professor at Wake Forest School of Medicine. His work focuses on neurodegenerative diseases, biomarker development, and advancing innovative approaches to AD research and clinical care.
Featured Speakers
- Dr. Simon Ducharme – Neuropsychiatrist and Clinician-Scientist, McGill University, Montreal, Quebec, Canada
- Dr. Noa Bregman – Director of the Cognitive Neurology unit, Tel Aviv Medical Center, Tel Aviv, Israel
- Dr. Suzanne Schindler – Associate Professor, Washington University School of Medicine in St. Louis, USA
- Dr. Sid O’Bryant – Executive Director of the Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, USA
- Prof. Charlotte Teunissen – Professor in Neurochemistry, Amsterdam UMC, Amsterdam, The Netherlands
The UNLOK Educational Platform is owned and managed by AD/PD™. This is an AD/PD™ initiative in educational partnership with Eisai and Biogen. This content is intended for healthcare professionals only for educational and informational purposes and does not substitute for sound medical judgment or clinical decision-making in the context of medical treatment. AD-M2558 | June 2026